NKGen Biotech Korea

At a glance

NKGen Biotech Korea filed 50 disclosures in the last 12 months, including 3 issuance and 1 5% holder. The most recent key filing was on Apr 22.

Revenue for 2025 was ₩7.9B, down 10.7% on 2024. It made an operating loss of ₩2.5B. Debt was 101% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩3.7B and operating loss of ₩1B.

The 2025 annual report lists 70 employees with an average tenure of 8.3 years. Its 6 directors and auditors were paid ₩47.2M each on average. It paid no cash dividend for 2025. NKGen Biotech, Inc. and related parties held 64.50% at year end.

From the 2025 annual report

Staff: 70 (26 men, 44 women), of whom 0 on fixed-term contracts. Directors and auditors: 6, paid ₩330.3M in total.

No cash dividend was paid for 2025.

Largest shareholder

NKGen Biotech, Inc. holds 64.49%; with 1 related party the group holds 64.50% of common shares at year end (from 0.00% at the start of the year).

Source: 2025 annual business report (DART). How figures are combined

Financial summary